Candel Therapeutics (CADL) Free Cash Flow (2020 - 2025)
Candel Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$7.5 million for Q4 2023.
- On a quarterly basis, Free Cash Flow fell 11.59% to -$7.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$34.7 million, a 10.2% decrease, with the full-year FY2025 number at -$38.4 million, down 42.18% from a year prior.
- Free Cash Flow hit -$7.5 million in Q4 2023 for Candel Therapeutics, up from -$8.9 million in the prior quarter.
- Over the last five years, Free Cash Flow for CADL hit a ceiling of -$1.3 million in Q3 2020 and a floor of -$10.9 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$6.9 million across 4 years, with a median of -$7.5 million in 2023.
- Biggest five-year swings in Free Cash Flow: tumbled 470.56% in 2021 and later grew 0.61% in 2023.
- Tracing CADL's Free Cash Flow over 4 years: stood at -$4.8 million in 2020, then dropped by 19.05% to -$5.7 million in 2021, then decreased by 16.56% to -$6.7 million in 2022, then fell by 11.59% to -$7.5 million in 2023.
- Business Quant data shows Free Cash Flow for CADL at -$7.5 million in Q4 2023, -$8.9 million in Q3 2023, and -$7.4 million in Q2 2023.